Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 522 (2) , 402-407
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education, Science and Technology (NRF-2014R1A6A1030318)
- Ministry of Education, Science and Technology (NRF-2018R1D1A3B07046915)
This publication has 23 references indexed in Scilit:
- Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cellsNucleic Acids Research, 2013
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeBreast Cancer Research, 2010
- Stability of the LATS2 Tumor Suppressor Gene Is Regulated by TristetraprolinJournal of Biological Chemistry, 2010
- The mRNA-Destabilizing Protein Tristetraprolin Is Suppressed in Many Cancers, Altering Tumorigenic Phenotypes and Patient PrognosisCancer Research, 2009
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001
- THE myc ONCOGENE: ITS ROLE IN TRANSFORMATION AND DIFFERENTIATIONAnnual Review of Genetics, 1986
- A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradationCell, 1986